Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.72 |
| ▸ | HTR2C | P28335 | 4/20 | 0.72 |
| ▸ | HTR7 | P34969 | 4/20 | 0.72 |
| ▸ | HTR6 | P50406 | 3/20 | 0.72 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27478864 | 0.88 | HTR2A (0.76) | HTR2AHTR2CHTR7HTR6GRM2 | |
| SCHEMBL12642700 | 0.87 | HTR2A (0.55) | HTR2AHTR2CHTR7HTR6KDM4E | |
| SCHEMBL4227924 | 0.87 | HTR2A (0.74) | HTR2AHTR2CHTR7HTR6GRM2 | |
| SCHEMBL14495105 | 0.85 | HTR2A (0.72) | HTR2AHTR2CHTR7HTR6GRM2 | |
| SCHEMBL4739633 | 0.85 | KDM4E (0.63) | HTR2ACACNA1GKDM4E | |
| SCHEMBL5367392 | 0.85 | HTR2A (0.71) | HTR2A | |
| SCHEMBL4703785 | 0.82 | TDP1 (0.57) | HTR2AHTR2CHTR7HTR6CYP1A2 | |
| SCHEMBL14495108 | 0.82 | HTR2A (0.67) | HTR2AHTR2CHTR7HTR6GRM2 | |
| SCHEMBL14401632 | 0.82 | HRH3 (0.70) | HTR2AHTR2CHTR7HTR6KDM4E | |
| SCHEMBL29280905 | 0.80 | HTR2A (0.57) | HTR2AHTR2CHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362589-B1 | Use of R(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol for the treatment of sleep disorders | AVENTIS PHARMA INC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1937265-A2 | COMINATION OF A HYPNOTIC AGENT AND R(+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1289527-B1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL OR ITS PRODRUG TO TREAT DEMENTIA OR COGNITIVE IMPAIRMENT | AVENTIS PHARMA INC (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007024599-A2 | COMINATION OF A HYPNOTIC AGENT AND R(+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-7132433-B2 | Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of behavioral or psychological symptoms associated with a disease | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20050272773-A1 | Use of R (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-flurophenyl)-ethyl]-4- piperidinemethanol for the treatment of sleep disorders and process for making pharmaceutical composition | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-6939879-B2 | Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia | AVENTIS PHARMACEUTICALS INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040204457-A1 | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis | AVENTIS PHARMACEUTICALS INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040002516-A1 | Use of R (+)-alpha-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders | AVENTIS PHARMACEUTICALS INC. | 2004-01-01 | — | — | US | disclosed |
| EP-0796619-A1 | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders | MERRELL PHARMACEUTICALS INC. (US) | 1997-09-24 | — | — | EP | disclosed |
| US-5618824-A | ADMINISTERING N-ARALKYL PIPERIDINEMETHANOL DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0749309-A1 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS WITH 5-HT 2? ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5561144-A | TREATMENT OF SCHIZOPHRENIA | MERRELL PHARMACEUTICALS INC. (US) | 1996-10-01 | — | — | US | disclosed |
| WO-1995024194-A1 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS WITH 5-HT2 ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0531410-B1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMA (US) | 1994-11-30 | — | — | EP | disclosed |
| EP-0531410-A4 | (+)--G(A)-(2,3-DIMETHOXYPHENYL)-1- 2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0531410-A1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL. | MERRELL DOW PHARMA (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5134149-A | Serotonin antagonist | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-28 | — | — | US | disclosed |
| WO-1991018602-A1 | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002516-A1 | Use of R (+)-alpha-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders | PNMT, HCRTR2, EBP | HTR2A 128/4885HTR2C 58/4885HTR7 82/4885 |
| US-20050272773-A1 | Use of R (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-flurophenyl)-ethyl]-4- piperidinemethanol for the treatment of sleep disorders and process for making pharmaceutical composition | OPRD1, EBP, ADRA1D | HTR2A 139/4885HTR2C 78/4885HTR7 87/4885 |
| US-20040204457-A1 | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis | COMT, PNMT, DBH | HTR2A 34/4885HTR2C 15/4885HTR7 68/4885 |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | HCRTR2, OPRD1, HCRTR1 | HTR2A 47/4885HTR2C 39/4885HTR7 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.